Biocon Ltd. — Board/Management Information 2024

Jun 11, 2024

==> picture [133 x 52] intentionally omitted <==

Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423

CIN : L24234KA1978PLC003417 www.biocon.com

BIO/SECL/SP/2024-25/37

June 11, 2024

To, The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street,Mumbai – 400 001	To, The Manager National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code – 532523	Scrip Symbol – BIOCON

Dear Sir/Madam,

Subject: Appointment of Interim Chief Financial Officer and Key Managerial Personnel of the Company.

Ref: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”), we would like to inform you that the Board of Directors at its meeting held today, has approved the appointment of Mr. Mukesh Kamath, Head - Business Finance R&D, as the Interim Chief Financial Officer and Key Managerial Personnel of the Company, pursuant to the provisions of Section 203 of the Companies Act, 2013 with effect from June 11, 2024, till the time new CFO is appointed by the Board.

The details as required under the Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed as Annexure I .

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For Biocon Limited

MAYANK Digitally signed by MAYANK VERMA VERMA Date: 2024.06.11 14:54:36 +05'30' _______

Mayank Verma Company Secretary & Compliance Officer Membership No: ACS 18776

Encl.: Annexure I

Annexure I

==> picture [133 x 52] intentionally omitted <==

Details as required under the Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023

Sl. No.	Particulars	Information
1.	Name	Mukesh Kamath
2.	Reason for change viz. appointment, resignation,removal,death or otherwise	Appointment
3.	Date of appointment/ cessation (as applicable) & term of appointment	June 11, 2024
4.	Brief profile (in case of appointment)	Attached asAnnexure II
5.	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Annexure II

Brief Profile of Mr. Mukesh Kamath

==> picture [94 x 123] intentionally omitted <==

Mr. Mukesh Kamath is a seasoned professional with more than 27 years of financial experience. Currently, Mukesh oversees Business Finance R & D, Indirect taxation, Capex, and other finance-related functions. Since joining Biocon in 2004 as a Management Executive, he has worked across all areas of finance within the Biocon Group.

Mr. Mukesh Kamath is a qualified Chartered Accountant from the Institute of Chartered Accountants of India and holds a B. Com degree from Kuvempu University.

Mukesh’s journey at Biocon began as an accountant for the construction of Biocon Park, one of the company's largest expansion projects at that time. In 2009, he moved to Clinigene International Limited, a 100% subsidiary of Biocon, where he independently managed all the areas of finance. Later in 2011, he rejoined Biocon to oversee a major joint development program with Mylan, as well as all capex projects.

Prior to joining Biocon, Mukesh has worked on various roles with United Breweries Limited, Infodesk Manipal Limited and Techsar Technologies Ltd.